Press coverage about Repligen Corporation (NASDAQ:RGEN) has trended somewhat positive on Thursday, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Repligen Corporation earned a news impact score of 0.19 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 46.7658561796624 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Repligen Corporation (RGEN) traded down 0.13% during trading on Thursday, reaching $38.22. 392,586 shares of the company traded hands. Repligen Corporation has a 52 week low of $26.16 and a 52 week high of $46.81. The company has a market capitalization of $1.43 billion, a P/E ratio of 74.79 and a beta of 1.18. The firm has a 50-day moving average price of $41.79 and a 200-day moving average price of $39.54.

Repligen Corporation (NASDAQ:RGEN) last issued its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.15 by $0.05. The company had revenue of $32.40 million during the quarter, compared to analyst estimates of $31.72 million. Repligen Corporation had a net margin of 15.61% and a return on equity of 9.90%. The firm’s revenue was up 11.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.16 EPS. Analysts forecast that Repligen Corporation will post $0.59 earnings per share for the current fiscal year.

A number of analysts have recently issued reports on the stock. Zacks Investment Research raised shares of Repligen Corporation from a “hold” rating to a “buy” rating and set a $43.00 price objective for the company in a research note on Thursday. Janney Montgomery Scott increased their price objective on shares of Repligen Corporation from $42.00 to $47.00 in a research note on Friday, June 23rd. TheStreet raised shares of Repligen Corporation from a “c+” rating to a “b-” rating in a research note on Friday, August 11th. BidaskClub raised shares of Repligen Corporation from a “hold” rating to a “buy” rating in a research note on Wednesday, August 9th. Finally, First Analysis raised shares of Repligen Corporation from an “equal weight” rating to an “overweight” rating and set a $47.00 price objective for the company in a research note on Monday. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Repligen Corporation has a consensus rating of “Buy” and an average price target of $45.40.

ILLEGAL ACTIVITY WARNING: “Repligen Corporation (RGEN) Earns Daily Media Sentiment Rating of 0.19” was first published by Marea Informative and is the sole property of of Marea Informative. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at

Repligen Corporation Company Profile

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Insider Buying and Selling by Quarter for Repligen Corporation (NASDAQ:RGEN)

Receive News & Stock Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related stocks with our FREE daily email newsletter.